View Financial HealthiFabric 배당 및 자사주 매입배당 기준 점검 0/6iFabric 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • 6h+ 1 more updateiFabric Corp. to Report Q1, 2026 Results on May 14, 2026iFabric Corp. announced that they will report Q1, 2026 results on May 14, 2026공시 • Apr 28iFabric Corp., Annual General Meeting, Jun 29, 2026iFabric Corp., Annual General Meeting, Jun 29, 2026. Location: ontario, markham Canada공시 • Aug 22iFabric Corp. Announces Publication of Groundbreaking Clinical Trial Providing the Infection Convenience Capability of PROTX2 and ecoPEL Treated ScrubsiFabric Corp. announced that the results of its clinical trial, "Antimicrobial-treated fabric scrubs can prevent pathogen proliferation on scrubs, has been officially published in the Journal of Hospital Infection, the editorially independent scientific publication of the Healthcare Infection Society. The aim of the Journal is to publish high quality research and information relating to infection prevention and control that is relevant to an international audience. The study-conducted by subsidiary Intelligent Fabric Technologies (North America) Inc. "IFTNA" at MemorialCare Saddleback Medical Center in Southern California under the leadership of Cheryl Westlake, PhD, RN, ACNS-BC, FHFSA, FAHA, FAAN;leen M. Young, MSN, RN, NPD-BC;andi Cassingham, MSN, RN; and Lisa Forsythe, MSN-Ed, RN, NPD- BC-marks the first successful antimicrobial textile trial of its kind to demonstrate statistically significant reductions in bacterial loads on scrubs worn in a real-world healthcare setting. This trial conclusively showed that scrubs treated with PROTX2 and PROTX2 combined with ecoPEL Fluorine-Free Durable Water Repellent (DWR) technology achieved significant and quantifiable reductions in surface bacterial contamination compared to untreated scrubs -proof that these proprietary technologies can deliver infection control performance unmatched in the industry. As a nonprofit, all revenue is reinvested into patient care, technology, and facility improvements, supported by the Saddleback Medical Center Foundation, which has fostered community partnership and philanthropy since founding. With over 500 affiliated clinicians, the company provide a full spectrum of inpatient, surgical, and outpatient services-including urgent care, advanced imaging, joint replacement, infusion therapy, stroke care, and rehabilitation-ensuring accessible, high-quality care for every stage of life. At Saddleback Medical Center, compassionate care, medical excellence, and community partnership remain at the heart of its mission.공시 • May 08iFabric Corp. to Report Q1, 2025 Results on May 15, 2025iFabric Corp. announced that they will report Q1, 2025 results Pre-Market on May 15, 2025공시 • Apr 23iFabric Corp., Annual General Meeting, Jun 24, 2025iFabric Corp., Annual General Meeting, Jun 24, 2025. Location: ontario, markham Canada공시 • Mar 14iFabric Corp. Provides Sales Guidance for the Full Year 2024iFabric Corp. provided Sales guidance for the full year 2024. For the year, the company expects sales to the range of $28 million to $32 million.공시 • Nov 10iFabric Corp. Announces Expansion MoveiFabric Corp. announced that it has executed a lease agreement for the rental of approximately 5,000 square feet of office space in Markham, Ontario, at a commercial office building near its current head office and warehouse location. The new offices will house the Canadian management and administrative personnel of the Company. After the move, the current Company owned building located at 525 Denison Street, Markham, Ontario, which currently comprises a mix of warehouse and office space, will be fully repurposed as warehouse space. The new office lease agreement is for a period of 5 years commencing on April 1, 2024, and expiring March 31, 2029, with the option to renew for a further period of 5 years. iFabric's personnel will be occupying temporary space at the new location, until such time as the required leasehold improvements to its new premises have been completed.공시 • Jul 06iFabric Corp. Announces the Successful Results of the Clinical Trial Utilizing Protx2 Treated ScrubsiFabric Corp. provided an update on the outcome of the clinical trial conducted by its wholly-owned subsidiary, Intelligent Fabric Technologies (North America) Inc. ("IFTNA"). The objective of the trial was to empirically demonstrate the reduction in bacterial loads on PROTX2 treated scrubs vs standard off the shelf untreated scrubs, when used in a healthcare environment. Three sets of scrubs were produced for the trial; one set treated with ProTX2 only, a second set with Protx2 and proprietary DWR (durable water repellant) technology and, a third set with no technologies applied (the control). The summary of the trial findings is that both the PROTX2 and the PROTX2 with DWR treated scrubs demonstrated statistically significant reductions in bacterial loads on the surfaces of scrubs, as compared to untreated scrubs. The term statistically significant is used to describe a result that is highly unlikely to occur by chance alone in a natural environment. The results achieved in the study demonstrate that proprietary technologies were uniquely responsible for the reduction in bacterial loads witnessed throughout the trial. The next and final phase of this trial is to submit the study to a recognized medical journal for peer review.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 IFAB.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: IFAB.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장iFabric 배당 수익률 vs 시장IFAB.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (IFAB.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Luxury)2.6%분석가 예측 (IFAB.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 IFAB.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 IFAB.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 IFAB.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: IFAB.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/13 14:21종가2026/05/13 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스iFabric Corp.는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Nicholas CortellucciAtrium ResearchDoug CooperBeacon Securities Limited
공시 • 6h+ 1 more updateiFabric Corp. to Report Q1, 2026 Results on May 14, 2026iFabric Corp. announced that they will report Q1, 2026 results on May 14, 2026
공시 • Apr 28iFabric Corp., Annual General Meeting, Jun 29, 2026iFabric Corp., Annual General Meeting, Jun 29, 2026. Location: ontario, markham Canada
공시 • Aug 22iFabric Corp. Announces Publication of Groundbreaking Clinical Trial Providing the Infection Convenience Capability of PROTX2 and ecoPEL Treated ScrubsiFabric Corp. announced that the results of its clinical trial, "Antimicrobial-treated fabric scrubs can prevent pathogen proliferation on scrubs, has been officially published in the Journal of Hospital Infection, the editorially independent scientific publication of the Healthcare Infection Society. The aim of the Journal is to publish high quality research and information relating to infection prevention and control that is relevant to an international audience. The study-conducted by subsidiary Intelligent Fabric Technologies (North America) Inc. "IFTNA" at MemorialCare Saddleback Medical Center in Southern California under the leadership of Cheryl Westlake, PhD, RN, ACNS-BC, FHFSA, FAHA, FAAN;leen M. Young, MSN, RN, NPD-BC;andi Cassingham, MSN, RN; and Lisa Forsythe, MSN-Ed, RN, NPD- BC-marks the first successful antimicrobial textile trial of its kind to demonstrate statistically significant reductions in bacterial loads on scrubs worn in a real-world healthcare setting. This trial conclusively showed that scrubs treated with PROTX2 and PROTX2 combined with ecoPEL Fluorine-Free Durable Water Repellent (DWR) technology achieved significant and quantifiable reductions in surface bacterial contamination compared to untreated scrubs -proof that these proprietary technologies can deliver infection control performance unmatched in the industry. As a nonprofit, all revenue is reinvested into patient care, technology, and facility improvements, supported by the Saddleback Medical Center Foundation, which has fostered community partnership and philanthropy since founding. With over 500 affiliated clinicians, the company provide a full spectrum of inpatient, surgical, and outpatient services-including urgent care, advanced imaging, joint replacement, infusion therapy, stroke care, and rehabilitation-ensuring accessible, high-quality care for every stage of life. At Saddleback Medical Center, compassionate care, medical excellence, and community partnership remain at the heart of its mission.
공시 • May 08iFabric Corp. to Report Q1, 2025 Results on May 15, 2025iFabric Corp. announced that they will report Q1, 2025 results Pre-Market on May 15, 2025
공시 • Apr 23iFabric Corp., Annual General Meeting, Jun 24, 2025iFabric Corp., Annual General Meeting, Jun 24, 2025. Location: ontario, markham Canada
공시 • Mar 14iFabric Corp. Provides Sales Guidance for the Full Year 2024iFabric Corp. provided Sales guidance for the full year 2024. For the year, the company expects sales to the range of $28 million to $32 million.
공시 • Nov 10iFabric Corp. Announces Expansion MoveiFabric Corp. announced that it has executed a lease agreement for the rental of approximately 5,000 square feet of office space in Markham, Ontario, at a commercial office building near its current head office and warehouse location. The new offices will house the Canadian management and administrative personnel of the Company. After the move, the current Company owned building located at 525 Denison Street, Markham, Ontario, which currently comprises a mix of warehouse and office space, will be fully repurposed as warehouse space. The new office lease agreement is for a period of 5 years commencing on April 1, 2024, and expiring March 31, 2029, with the option to renew for a further period of 5 years. iFabric's personnel will be occupying temporary space at the new location, until such time as the required leasehold improvements to its new premises have been completed.
공시 • Jul 06iFabric Corp. Announces the Successful Results of the Clinical Trial Utilizing Protx2 Treated ScrubsiFabric Corp. provided an update on the outcome of the clinical trial conducted by its wholly-owned subsidiary, Intelligent Fabric Technologies (North America) Inc. ("IFTNA"). The objective of the trial was to empirically demonstrate the reduction in bacterial loads on PROTX2 treated scrubs vs standard off the shelf untreated scrubs, when used in a healthcare environment. Three sets of scrubs were produced for the trial; one set treated with ProTX2 only, a second set with Protx2 and proprietary DWR (durable water repellant) technology and, a third set with no technologies applied (the control). The summary of the trial findings is that both the PROTX2 and the PROTX2 with DWR treated scrubs demonstrated statistically significant reductions in bacterial loads on the surfaces of scrubs, as compared to untreated scrubs. The term statistically significant is used to describe a result that is highly unlikely to occur by chance alone in a natural environment. The results achieved in the study demonstrate that proprietary technologies were uniquely responsible for the reduction in bacterial loads witnessed throughout the trial. The next and final phase of this trial is to submit the study to a recognized medical journal for peer review.